We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Early Sepsis Recognition Platform Could Identify Pre-Symptomatic Patients at POC Using Culture-Free Diagnostic Test

By HospiMedica International staff writers
Posted on 14 Nov 2022
Print article
Image: An early sepsis recognition platform could be more rapid, affordable and accessible (Photo courtesy of Pexels)
Image: An early sepsis recognition platform could be more rapid, affordable and accessible (Photo courtesy of Pexels)

Early sepsis recognition is vital in improving patient prognosis and reducing mortality. Now, a new diagnostic system for early-stage sepsis condition could allow doctors to predict the future appearance and evolution of sepsis within a short period of time and thus, provide a suitable clinical response even before the symptoms arise.

DeepUll (Barcelona, Spain), a biotech company, is creating rapid, affordable and accessible diagnostic solutions with a specific focus on culture-free diagnostics to enable sepsis recognition in pre-symptomatic patients. DeepUll’s technology aims to not only rapidly identify the causative infective agent(s) within a few hours, but will also provide phenotypic antimicrobial susceptibility results, thus reducing the unnecessary use of antimicrobials. The product will also utilize artificial intelligence (AI) to offer seamless medical decision support across all phases of patient management, from early disease recognition, to precise diagnostics, up to therapy guidance.

DeepUll’s first-in-class sepsis recognition platform is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. The product will be a desktop system with end-to-end automation with the aim to be placed in any clinical setting (laboratory, ER, ICU).

“Early identification of sepsis is absolutely crucial to a patient’s prognosis, but the tools caregivers have available today are woefully inadequate,” said Jordi Carrera, Chief Executive Officer and Co-Founder of DeepUll. “Our mission is to change this and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market.”

Related Links:
DeepUll

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Aortic Valve Replacement System
INTUITY Elite
New
Pediatric Phlebotomy Chair
2665M2 Extra Wide Pediatric Phlebotomy Chair

Print article

Channels

Critical Care

view channel
Image: Mesenchymal stromal cells are delivered directly into the lungs using a bronchoscope (Photo courtesy of Stem Cell Res Ther. 2025. DOI: 10.1186/s13287-025-04289-3)

Novel Intrabronchial Method Delivers Cell Therapies in Critically Ill Patients on External Lung Support

Until now, administering cell therapies to patients on extracorporeal membrane oxygenation (ECMO)—a life-support system typically used for severe lung failure—has been nearly impossible.... Read more

Surgical Techniques

view channel
Image: Intravascular imaging can improve outcomes for complex stenting procedures in patients with high-risk calcified coronary artery disease (Photo courtesy of Shutterstock)

Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.